The clinical use of HVPG measurements in chronic liver disease.
about
Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patientsHVPG signature: A prognostic and predictive tool in hepatocellular carcinomaFour-dimensional flow magnetic resonance imaging in cirrhosis.Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's LawInvasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond.The accuracy of ultrasonography for the evaluation of portal hypertension in patients with cirrhosis: a systematic reviewPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesClinical role of non-invasive assessment of portal hypertensionDiagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy.Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.The Role of Spleen Stiffness in Determining the Severity and Bleeding Risk of Esophageal Varices in Cirrhotic PatientsCirculating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.Invasive and non-invasive diagnosis of cirrhosis and portal hypertensionTransient elastography: Kill two birds with one stone?Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease.Phase-contrast MR flow imaging: A tool to determine hepatic hemodynamics in rats with a healthy, fibrotic, or cirrhotic liver.EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study.Transjugular intravascular ultrasound for the evaluation of hepatic vasculature and parenchyma in patients with chronic liver disease.PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertensionCorrelation of aspartate aminotransferase/platelet ratio index with hepatic venous pressure gradient in cirrhosisA novel noninvasive assessment of hepatic venous pressure gradient and portal pressure computed from computed tomography angiography.Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement.The effect of carvedilol and propranolol on portal hypertension in patients with cirrhosis: a meta-analysis.Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans.Hepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis.Comparison of hepatic venous pressure gradient and endoscopic grading of esophageal varicesApplication of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhoticsLong-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI gradeHepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.A histologic scoring system for prognosis of patients with alcoholic hepatitisHepatic venous pressure gradient: clinical use in chronic liver disease.Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression.Portal hypertension: pathophysiology, diagnosis, and treatment.Assessing portal hypertension in liver diseases.Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension.Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar.Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.
P2860
Q24658600-EDBC6737-1386-4B8A-AE4A-E60BE7CE07F7Q26738597-CD0105AF-3CCD-4B4D-93D8-68714139065BQ26769606-4E11F9F2-9240-4388-8AFC-887C0DF7E2DBQ26797581-78490C18-6C17-475A-BFFA-997D051664DFQ26825287-32CD5B33-B63B-421E-9523-328E5D8A832AQ26853160-43084AAF-5FBE-4A98-B2D4-AA1F7D667D70Q26996085-2FBA03BD-7317-4AC0-A900-112A89359593Q28272678-7AFF2C95-2314-4AA6-9ECC-AFC3016E3E57Q28468382-E1A1E185-2D6B-4AE6-81D3-8E3F0E34D1E5Q30355947-098C70DC-5CA4-444A-A994-4368BF29B739Q30357059-F1050B38-8585-4C70-AE23-96EFBCC7EBD5Q30400389-951C70BF-1B76-49E2-AE3A-99348561703EQ30418874-BA68074E-D20F-46F2-9607-25BA66470624Q30439743-CB75B62C-A94A-483A-9B21-C92A311CF94EQ30454363-81A832A0-0725-4030-8F4D-CB140D44122BQ31090448-AAFA9229-669B-4612-BD23-0E6FF28E99E5Q31166756-61E460AC-CF4C-492F-BBB1-3E79CF2A2A6EQ33435692-BB05A203-2DC0-4A70-9EDB-8279C049CFC3Q34143198-B19D5698-0BD6-4878-BA24-DF7CF2D89AC1Q34268818-94C804A1-5407-41B3-A8FE-7BB5E7FA09FCQ34418673-E9D43FD4-F8DE-4D33-A493-CFE754C65363Q34466792-80577326-44E1-4BF2-8226-EB57C3CF556CQ35237338-5D0621FC-40BB-4021-AD27-635E041DD5D6Q35707623-21B8860D-13B2-4E8C-8115-1A7A0EACCB74Q35818743-8EAFB487-E80E-40B1-9662-3800C19E221AQ35928746-BD24D1A1-DABF-4AC8-8125-9BADEFBBB238Q36096110-D973C271-1494-4D93-8A35-A42229C2ED2DQ36412440-8C4E68AD-A4EF-45DB-BE65-3F8CBA74A35AQ36682618-A4E27DCB-4E32-49A3-A2C6-6570FE381C14Q36709059-87866E61-F9BA-43BC-9DD4-3028DBED9369Q37174913-5D24CC6E-0461-4AAB-96B4-5E8545480DDCQ37696171-7E4FD542-A4E5-4A5A-A4FF-5176D743F2EAQ37710980-AE57250A-B30B-4787-AB65-8A3A0083FE66Q37711328-52A3690D-D2D7-48C0-9EDD-01166208BCB0Q37777154-F5B4CD20-F8E0-4EAC-AB11-514F463407EEQ37850467-81F4BCBD-B305-4948-B8E9-2A80406F589FQ38077823-BEB12607-95F8-4185-8DCC-7EB391E9D96FQ38088585-3EC5B94D-B904-413D-B4A8-8B5F675BB9ADQ38218544-A1DCA9C3-9F79-4C1F-B998-7DD377337A34Q38248394-365B7401-0298-404F-9BCB-8A807D1C4ADE
P2860
The clinical use of HVPG measurements in chronic liver disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The clinical use of HVPG measurements in chronic liver disease.
@en
The clinical use of HVPG measurements in chronic liver disease.
@nl
type
label
The clinical use of HVPG measurements in chronic liver disease.
@en
The clinical use of HVPG measurements in chronic liver disease.
@nl
prefLabel
The clinical use of HVPG measurements in chronic liver disease.
@en
The clinical use of HVPG measurements in chronic liver disease.
@nl
P2860
P1476
The clinical use of HVPG measurements in chronic liver disease.
@en
P2093
Annalisa Berzigotti
Jaime Bosch
P2860
P2888
P304
P356
10.1038/NRGASTRO.2009.149
P407
P577
2009-09-01T00:00:00Z